AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease

- 98 percent of patients across all major HCV genotypes (GT1-6) with severe chronic kidney disease (CKD), including patients on dialysis, achieved SVR12 with 12 weeks of G/P in the primary intent-to-treat analysis, regardless of previous treatment status or presence of compensated cirrhosis - 100 percent of patients achieved SVR12 in a modified intent-to-treat analysis - G/P is an investigational, pan-genotypic, once-daily, ribavirin-free, fixed-dose com...

Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C

 97.5 percent of chronic HCV infected patients without cirrhosis and new to treatment across all major genotypes (GT1-6) achieved SVR12 with 8 weeks of G/P Across the 8-week arms of three registrational studies, no patients discontinued treatment due to adverse events G/P is an investigational, pan-genotypic, once-daily, ribavirin-free regimen for the treatment of chronic HCV NORTH CHICAGO, Ill., Nov. 11, 2016 /PRNewswire/ -- AbbVie (N...

AbbVie hepatitis C combo shows high cure rates

AbbVie presented new data on its once-daily hepatitis C virus (HCV) combination, revealing high cure rates across all six major HCV genotypes. The new phase II data on NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 - which recently started pivotal trials - showed that 97-98% of patients with genotype 1-3 HCV and no cirrhosis achieved a cure (sustained virologic response or SVR) within eight weeks of starting treatment. Meanwhile, in paten

AASLD 2015: New AbbVie hepatitis C pan-genotypic combination cures 97% – 100% in early study

A combination of two experimental direct-acting antivirals developed by AbbVie cured 97%-100% of non-cirrhotic people with genotype 1 hepatitis C infection in a mid-stage phase 2 study presented this week at the AASLD Liver Meeting in San Francisco.The SURVEYOR-1 study assessed the effectiveness and safety of two experimental next-generation direct-acting antivirals. ABT-493 is an HCV NS3/4A protease inhibitor active against all genotypes of hepatitis C. A